title: Exovascular application of epigallocatechin-3-O-gallate-releasing electrospun poly(L-lactide glycolic acid) fiber sheets to reduce intimal hyperplasia in injured abdominal aorta.
abstract: Intimal hyperplasia is an excessive ingrowth of tissue resulting in chronic structural lesions commonly found at sites of atherosclerotic lesions, arterial angioplasty, vascular graft anastomoses, and other vascular abnormalities. Epigallocatechin-3-O-gallate (EGCG) was shown to elicit antioxidant, anti-proliferative, and anti-thrombogenic effects. In this study, we used an electrospinning technique to synthesize EGCG-eluting biodegradable poly(L-lactide glycolic acid) (PLGA) fiber sheets for local delivery of EGCG and investigated the effect of their exovascular application on intimal hyperplasia following balloon-induced abdominal aorta injury in a rabbit experimental model. The morphology of the composite sheets was characterized using scanning electron microscopy and Fourier transform-infrared spectroscopy. EGCG was loaded and dispersed into the PLGA-based electrospun fibers. The EGCG-loaded PLGA sheets exhibited sustained EGCG release following the initial 24 h of burst release in phosphate-buffered saline. In vivo studies demonstrated significant inhibition of intimal hyperplasia following the application of the EGCG-eluting electrospun PLGA fiber sheets, compared with vehicle PLGA controls. In conclusion, our results show that exovascular application of EGCG-eluting PLGA electrospun fiber sheets may provide a useful system for the effective local delivery of drugs for the prevention of intimal hyperplasia.
authors.affiliation: Cellbiocontrol Laboratory, Department of Medical Engineering, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
authors.forename: Mi Hee
authors.initials: MH
authors.lastname: Lee
authors.forename: Byeong-ju
authors.initials: BJ
authors.lastname: Kwon
authors.forename: Min-Ah
authors.initials: MA
authors.lastname: Koo
authors.forename: Eui Hwa
authors.initials: EH
authors.lastname: Jang
authors.forename: Gyeung Mi
authors.initials: GM
authors.lastname: Seon
authors.forename: Jong-Chul
authors.initials: JC
authors.lastname: Park
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage; D001012:Aorta, Abdominal / Q000187:drug effects / Q000293:injuries*; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D004058:Diffusion; D004343:Drug Implants / Q000008:administration & dosage* / Q000737:chemistry; D004595:Electroplating / Q000379:methods; D004730:Endothelium, Vascular / Q000187:drug effects*; D019344:Lactic Acid / Q000737:chemistry*; D008297:Male; D008567:Membranes, Artificial; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry / Q000648:ultrastructure; D058608:Nanopores / Q000648:ultrastructure; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D016062:Porosity; D011817:Rabbits; D016896:Treatment Outcome; D057772:Vascular System Injuries / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000975:Antioxidants; D004343:Drug Implants; D008567:Membranes, Artificial; D053769:Nanocapsules; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D002392:Catechin; C045651:epigallocatechin gallate